Scarica l'app Stockscreener
1.66
11.41%
0.17
Pre-mercato:
1.58
-0.08
-4.82%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NMRA Giù?
Forum
Previsione
Neumora Therapeutics Inc Borsa (NMRA) Ultime notizie
Neumora Therapeutics | 8-K: Current report - Moomoo
Neumora Therapeutics Shares Rise on Positive Obesity Drug Results - Moomoo
NMRA|Neumora Therapeutics Inc|Price:1.456|Chg%:-0.034 - TradingKey
New toxicology data support advancement of Neumora Therapeutics’ NMRA-215 - BioWorld News
Neumora Therapeutics Plans Q4 IND Filing for Obesity Drug After Repeat Toxicology Study - marketscreener.com
Neumora reports favorable toxicology results for obesity drug - Investing.com
Neumora reports favorable toxicology results for obesity drug By Investing.com - Investing.com Canada
Neumora's Repeat NMRA-215 Rat Study Found No Unexpected Adverse Findings - Stock Titan
Neumora Therapeutics Inc (NMRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neumora Therapeutics Inc (NMRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NMRA|Neumora Therapeutics Inc|Price:1.490|Chg%:-0.070 - TradingKey
Neumora Therapeutics Inc (NMRA) Cash Flow - TradingKey
TradingKey - TradingKey
Neumora Therapeutics (NASDAQ:NMRA) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Siren L.L.C. Buys 2,209,039 Shares of Neumora Therapeutics, Inc. $NMRA - MarketBeat
Neumora Therapeutics (NMRA) AGM 2026 Summary - Quartr
Neumora Therapeutics Target of Unusually Large Options Trading (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Price Target Cut to $5.00 by Analysts at Royal Bank Of Canada - MarketBeat
Neumora Therapeutics Is Maintained at Outperform by RBC Capital - Moomoo
RBC Cuts Price Target on Neumora Therapeutics to $5 From $7, Keeps Outperform, Speculative Risk - marketscreener.com
Neumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant Discontinuation - Yahoo Finance
Neumora Therapeutics (NMRA) Edges Higher Amid Modest Gains, Holds Near Key SupportPut Flow Alert - dars.gov.et
A Quick Look at Today's Ratings for Neumora Therapeutics(NMRA.US), With a Forecast Between $5 to $7 - Moomoo
Neumora Therapeutics (NMRA) Stock Slides 3.76% as Biotech Sentiment Remains FragileMcClellan Summation - dars.gov.et
Why Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to Buy - Yahoo Finance
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 2000 Index - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 2500 Growth Benchmark - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 2000 Growth Benchmark - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 3000E Growth Benchmark - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell Microcap Index - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 2500 Index - marketscreener.com
Neumora Therapeutics Inc (NMRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of - The National Law Review
NMRA Slides As Neumora Kills Navacaprant After Phase 3 Blowup - StocksToTrade
NMRA Stock Drops As Neumora Axes Failed Depression Drug - timothysykes.com
NMRA IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the - TMX Newsfile
Price to book forward of Neumora Therapeutics, Inc. – NASDAQ:NMRA - TradingView
NMRA Slides As Neumora Axes Navacaprant After Phase 3 Failure - timothysykes.com
Price to sales forward of Neumora Therapeutics, Inc. – NASDAQ:NMRA - TradingView
Enterprise value to EBIT forward of Neumora Therapeutics, Inc. – NASDAQ:NMRA - TradingView
Price to earnings forward of Neumora Therapeutics, Inc. – NASDAQ:NMRA - TradingView
Price to sales forward of Neumora Therapeutics, Inc. – BOATS:NMRA - TradingView
Enterprise value to EBITDA forward of Neumora Therapeutics, Inc. – BOATS:NMRA - TradingView
Price to earnings forward of Neumora Therapeutics, Inc. – BOATS:NMRA - TradingView
Enterprise value to revenue forward of Neumora Therapeutics, Inc. – BOATS:NMRA - TradingView
Neumora Therapeutics, Inc. Actuals & Estimates (NASDAQ:NMRA) - TradingView
NMRA Forecast — Price Target — Prediction for 2027 - TradingView
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials - Stocktwits
Neumora stock plunges 49% after late-stage depression drug failure - MSN
Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Neumora stock price target lowered to $4 by Mizuho on trial failure - Investing.com
Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds - The National Law Review
Neumora Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Pinto Joshua - Moomoo
Neumora Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Aurora Daljit Singh - Moomoo
Neumora Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Neumora Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer BERNS PAUL L - Moomoo
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud - Business Wire
Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Rx Rundown: Sanofi, Neumora Therapeutics, Uniqure and more - Medical Marketing and Media
Neumora Therapeutics Inc (NMRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neumora Therapeutics Inc (NMRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Robbins LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors - GuruFocus
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics, Inc. (NMRA) for Potential Securities Fraud - ACCESS Newswire
Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression Data - Yahoo Finance
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):